Neonatal survival rates in 860 singleton live births at 24 and 25 weeks gestational age. A Canadian multicentre study

Authors: Effer, Sidney B.1; Moutquin, Jean-Marie2; Farine, Dan3; Saigal, Saroj4; Nimrod, Carl5; Kelly, Edmond3; Niyonsenga, Theophile6

Source: BJOG: An International Journal of Obstetrics & Gynaecology, Volume 109, Number 7, July 2002 , pp. 740-745(6)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Objective

To determine the current survival rate of singleton living newborns born at gestational age of 24 and 25 weeks, using obstetric factors available to the physician before birth. Design

Retrospective study of all live births in 13 of 17 Canadian tertiary centres. Population

All singleton live births without congenital abnormalities. Methods

During the years 1991-1996, data were abstracted from clinical databases and charts of 860 live births, in 13 of the 17 tertiary centres in Canada, all with major neonatal intensive care units. Newborn survival was defined as alive at discharge from neonatal intensive care unit. Abstracted elements included gestational age, maternal antenatal corticosteroid treatment, birthweight, gender, fetal presentation and mode of delivery. Results

Average survival rates increased from 56.1% at 24 weeks ( n= 406 ) to 68.0% at 25 weeks ( n= 454 ). Survival rates ranged from 53.1% at day 168 to 81.6% at day 181 ( r = 0.802, P < 0.05 ). Steroid administration improved the survival rates at 24 and 25 weeks compared with that of unexposed fetuses, respectively (58.9%vs 41.8%; OR 1.70; 95% CI 1.03-2.08 and 74.2%vs 56.8%; OR 2.19; 95% CI 1.41-3.38). Caesarean delivery for breech presentation improved survival compared with vaginal delivery, both at 24 and 25 weeks (56.1%vs 36.0%; OR 2.19; 95% CI 1.10-4.34, and 68.7%vs 55.2% OR 1.78; 95% CI 0.093-3.43). Female neonates displayed better survival rates (59.6%vs 52.1% OR 1.36; 95% CI 0.92-2.01, and 72.6%vs 63.1% OR 1.51; 95% CI 1.02-2.25) at 24 and 25 weeks, respectively. Explanatory regression model confirmed these factors as prognostic variables associated with survival. Conclusions

This extensive collaborative study confirms that several prognostic factors, known before birth, including gestational age in days, steroid treatment, mode of presentation and fetal sex may help obstetricians, neonatologists and parents in their decision-making process at 24 and 25 weeks of pregnancy.

Document Type: Research article

DOI: 10.1111/j.1471-0528.2002.01067.x

Affiliations: 1: British Columbia Women's Hospital, Vancouver, British Columbia, Canada 2: CHU Sherbrooke, Sherbooke, Québec, Canada 3: Mount Sinai Hospital, Toronto, Ontario, Canada 4: McMaster University Hospital, Hamilton, Ontario, Canada 5: Ottawa General Hospital, Ottawa, Ontario, Canada 6: Centre de Recherche Clinique, Sherbrooke University, Sherbooke, P.Q., Canada

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A